Skip to content
MarketScale
‹ Back to IndustriesHealthcare

TPC’s Interventional Cardiology (IC) Has Saved Members $9 Million

Achieving system value can be challenging for small, independent hospitals. However, when these institutions band together, they find strength in their collective power to negotiate for services and supplies. TPC began its Interventional Cardiology (IC) program to drive savings for Members for products in this category, including balloons, stents and guide wires. It became a…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Achieving system value can be challenging for small, independent hospitals. However, when these institutions band together, they find strength in their collective power to negotiate for services and supplies. TPC began its Interventional Cardiology (IC) program to drive savings for Members for products in this category, including balloons, stents and guide wires. It became a highly Member-engaged initiative that yielded impressive results.

IC technology can be an alternative to more expensive and risky open-heart surgery. In IC, physicians insert interventional stents through the femoral artery and place them in the heart to hold the vessels open, allowing continued blood flow to the heart and vital organs. IC is a simpler and less invasive procedure for physicians to perform compared to others – removing the need to harvest veins or transfuse blood. Best of all, it’s an outpatient procedure, so patients heal faster without the need for lengthy hospital stays.

The TPC IC initiative engaged both the Cardiology Clinical Value Analysis Team (CVAT) and the Cardiology Physician Sub-Committee (PSC). When Members decided to tackle this category, one of the main concerns was individual physician commitment to existing IC vendor relationships. The goal of the TPC process was to select a common vendor or vendors that provide clinically acceptable quality at the best overall value. As a result, all Members were asked to move as a group from their current facility-specific vendors to collectively selected vendors that would serve the membership as a whole. While not a challenge to do, it did require change.

The IC initiative was created as a pre-commit program. By agreeing to formally adhere to commitment levels with the awarded vendor, TPC Members act as a virtual integrated delivery network (IDN) and demonstrate the integrity of their contracting process to the supplier community. Ultimately, TPC’s IC program offers its Members the ability to access clinically-acceptable products while also reducing overall costs, as they purchase in aggregate with other TPC Members.

To begin the process, TPC met with the administrative teams at each hospital to understand their concerns and desires related to the IC initiative. TPC then used this information as part of a strategy session with the Physician Sub-Committee (PSC) that consisted of cardiology physician representatives from each Member hospital. The physicians in the Interventional Cardiology PSC played an integral role in providing input into the TPC request for proposal (RFP) before sending it out to the vendor community. Vendors were made aware of the collaboration between clinicians and hospital administration to drive the best possible results for this initiative.

The strength of aggregated volume and solid commitment from the membership resulted in proposals from the vendor community that were highly competitive and drove significant value for the Members. The results? Since its introduction in 2010, TPC’s IC program has saved its members $9 million while delivering optimal patient care. And the program has continued to evolve over the years. As contracts term, TPC Members have been successful in evaluating the marketplace and moving market share, as needed, to those vendors who can provide the most comprehensive value. In addition, to date, TPC continues to meet its commitment with the category’s preferred vendors, with Members maintaining greater than 80% compliance.

“Our Cardiology CVAT and PSC success in Interventional Cardiology has been one of the best examples of what makes TPC great. Historically, Interventional Cardiology has seen a high level of physician preference, but by engaging directly with our physicians and clinicians, and working through the processes that the TPC has established, we have delivered substantial value from this category throughout the years,” explained Luke Martin, Director of Materials Management for Shannon Medical Center.

Interventional cardiology offers a less invasive way for physicians to treat heart problems, but requires sophisticated equipment that can be costly. When independent hospitals collaborate through a coalition model, they have increased negotiating power and a collective voice that can generate savings beyond what can be achieved alone. TPC is the epitome of a value-based partnership of community-based hospitals working together as a single system.

Stronger Together. Superior Results.

Read more at tpc1.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512